A new law will let Medicare bargain for the first time. But a health policy scholar explains why it’s unlikely to make much of a difference in how much seniors – or anyone else – pays for their meds.
Academic rigour, journalistic flair
Articles on Copayments
Displaying all articles
A cancer diagnosis is one of the scariest of all. The pain and fear are worsened by a confusing landscape of bills, opaque billing systems and changing insurance rules, rates and reimbursements.
Frustrated with Congress for its failure to replace Obamacare, President Trump took matters into his own hands and issued an executive order to nix parts of it. How his order will play out is unknown.
The Medicare rebate indexation freeze will hit hardest for people with the poorest health, greatest need for primary healthcare and least capacity to afford increases in the cost of visiting a GP.
Academics are trained to answer important questions about health policy, and collaborating with industry on research can have a big impact.
Top contributors
-
Professor of Surgery, Division of Public Health Sciences, Washington University in St. Louis
-
Professor, Health Policy and Management, Texas A&M University
-
Dean of the Sol Price School of Public Policy; Distinguished Professor of Pharmacy, Public Policy, and Economics, University of Southern California
-
Quintiles Professor of Pharmaceutical Development and Regulatory Innovation, Schaeffer Center for Health Policy and Economics, University of Southern California
-
Research Assistant - School of Economics, University of Sydney
-
Professor of Economics, University of Sydney
-
Associate Professor of Public Health, Texas A&M University
